Digital Content 
NEWS #PharmaBuzz
03 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/03/2990362/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NMPA-Conditional-Approval-for-ELUNATE-Fruquintinib-in-Combination-with-TYVYT-Sintilimab-Injection-for-the-Treatment-of-Advanced-Endometrial-C.html
02 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-delivers-oral-presentation-of-clinical-data-of-a-randomized-controlled-phase-1b-study-evaluating-ibi310-anti-ctla-4-monoclonal-antibody-in-combination-with-sintilimab-as-neoadjuvant-treatment-of-colon-cancer-at-2024-asc-302161380.html
01 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/02/2855618/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NDA-Acceptance-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-the-Treatment-of-Advanced-Endometrial-Cancer-with-Priority-Review-St.html
26 Mar 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-neoshot-of-ibi310-anti-ctla-4-monoclonal-antibody-in-combination-with-sintilimab-for-msi-hdmmr-colon-cancer-neoadjuvant-therapy-302099295.html
27 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-and-xuanzhu-enter-into-clinical-trial-collaboration-investigating-combination-therapy-of-sintilimab-pd-1-inhibitor-and-a-novel-adc-candidate-for-advanced-solid-tumors-in-china-302022707.html
12 Dec 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/12/13/2795176/0/en/HUTCHMED-Announces-that-it-has-Completed-Enrollment-of-a-Phase-II-III-Trial-of-Fruquintinib-in-Combination-with-Sintilimab-for-Advanced-Renal-Cell-Carcinoma-in-China.html
Share 